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Keywords:
HTPR — high on treatment platelet reactivity
PCI — percutaneous coronary intervention
MPA —maximum platelet aggregation
ADP-LTA — adenosine diphosphate light
transmission aggregometryObjectives: To compare the pharmacodynamic effects of clopidogrel reloading vs. switching to prasugrel or
ticagrelor in high on treatment platelet reactivity (HTPR) patients undergoing percutaneous coronary interven-
tion (PCI).
Methods: Prospective, single-centre study wherein consecutive patients undergoing nonemergent PCI
showing HTPR on 600 mg clopidogrel loading were randomized to either clopidogrel reloading (300 mg load,
75 mg OD) or prasugrel (60 mg load, 10 mg OD-in patients N 60 kg) or ticagrelor (180 mg load, 90 mg BD).
HTPR is deﬁned as maximum platelet aggregation (MPA) N 46% assessed by 5 μmol/L adenosine diphosphate
light transmission aggregometry (ADP-LTA) assay after more than 6 h of clopidogrel loading. Platelet function
were assessed at baseline, 6 h or more after clopidogrel loading, 2 h after reloading, day 1 and day 30 post-PCI.
Results: 107 patients enrolled in the study, 32 (29.9%)were found to haveHTPR. 10 (9.3%) patientswere reloaded
with clopidogrel, 10 (9.3%) with prasugrel and 12 (11.2%) with ticagrelor. Mean MPA in clopidogrel, prasugrel
and ticagrelor reloaded patientswas 42.6±12.5%, 15.8± 8.6% and 14.6±7.2% respectively at 2 h after reloading
andwas 43.7± 13.5%, 15.4± 5.6% and 12.6±4.6% on day 1 post-PCI. TheMPA signiﬁcantly reduced in prasugrel
and ticagrelor cases and not in clopidogrel, also prasugrel and ticagrelor had almost similar MPA after the reload.
There was no patient with continued HTPRwith ticagrelor or prasugrel while 50% (5/10) of clopidogrel reloaded
patients had HTPR. The pharmacodynamic efﬁcacy of maintenance with prasugrel or ticagrelor was better than
clopidogrel (MPA at day 30 post-PCI; 15 ± 9.7%, 13.9 ± 5.1% and 50.4 ± 13.1% respectively).
Conclusion: In patients undergoing PCI exhibitingHTPR after clopidogrel loading, ticagrelor or prasugrel reloading
produced improved platelet inhibition which was better than clopidogrel reload and this effect was sustained
during maintenance phase.
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Current guidelines recommend treating patients undergoing
percutaneous coronary intervention (PCI) and drug-eluting stent implan-
tationwith a loading dose of P2Y12 receptor antagonist and continuation
of same for at least 1 year [1]. Clopidogrel resistance has been deﬁned as
high on treatment platelet reactivity (HTPR) [2]. Variable antiplatelet
responses to clopidogrel are primarily based on metabolic phenotype
of cytochrome 2C19 (CYP2C19) genotype. Patients who are carriers of
loss-of-function alleles in the hepatic CYP2C19 system have lower
clopidogrel activemetabolite levels and are thus clopidogrel resistant [3,4].
High on treatment platelet reactivity (HTPR) while on clopidogrel
has been seen to be associated with high adverse event rates in patients
undergoing percutaneous coronary intervention (PCI) [5–7]. Newery, Sanjay Gandhi Postgraduate
6014, Uttar Pradesh, India.
pen access article under the CC BY-NP2Y12 inhibitors, prasugrel and ticagrelor, are accompanied by a stron-
ger and more consistent antiplatelet action compared with clopidogrel
[8–17]. However, there is limited data on the effects of clopidogrel
reloading vs. switching to prasugrel or ticagrelor in this group of HTPR
patients.
In pharmacodynamic study, in post-PCI patients exhibiting HTPR,
prasugrel was more effective than a double maintenance dose of
clopidogrel in reducing platelet reactivity (PR) [18]. Ticagrelor therapy
was associated with greater platelet inhibition compared with
clopidogrel in stable CAD patients with HTPR following a 300-mg
clopidogrel loading dose [19]. In the present study, we aimed to com-
pare the pharmacodynamic effects of clopidogrel reloading vs.
switching to prasugrel or ticagrelor in clopidogrel resistant Indian pa-
tients being taken up for PCI.
2. Methods
Study was a prospective randomized, single-centre, 3-arm, parallel-
design study to evaluate the pharmacodynamic response of clopidogrelC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tance patients being taken up for PCI.2.1. Study population
Patients aged 18 to 75 years being taken for elective coronary angi-
ography and possible revascularisation were included in the study.
Patients with acute STEMI and those undergoing urgent coronary
angiography and possible revascularisation were excluded from the
study. Patients were also excluded if they were already on antiplatelet
therapy except aspirin and clopidogrel, had contraindications to anti-
platelet therapy, were on chronic oral anticoagulation treatment, or
had a history of bleeding diathesis. Patients were also excluded if
there was any history of ischemic or hemorrhagic stroke, intracranial
neoplasm, arteriovenous malformation or aneurysm, a history of tran-
sient ischemic attack, history of active bleeding, or were on dialysis. A
written informed consent was obtained prior to the procedure in all pa-
tients as per institution protocol. Approval of the institutional ethics
committee was taken for study.2.2. Study Design
Baseline platelet function test was done before clopidogrel loading.
All patients clopidogrel naive or otherwise received an initial loading
dose of clopidogrel 600mg in the night prior to the planned PCI. Platelet
function was assessed after 6 or more hours of clopidogrel loading.
The HTPR patients were randomly assigned in 1:1:1 ratio, using
computerized random-number generation to receive 1 of the following
3 regimens: 1) clopidogrel 300mg loading dose (LD) followed by 75mg
OD maintenance dose (MD); 2) prasugrel 60-mg loading dose (LD)
followed by 10-mg OD maintenance dose (MD) in patients ≥60 kg or
3) ticagrelor 180-mg loading dose (LD) followed by 90-mg BD mainte-
nance dose (MD). Patients with no HTPR (clopidogrel sensitive) were
continued on Clopidogrel 75 mg OD. All patients received aspirin
325 mg stat followed by 150 mg/day if aspirin naive or aspirin 150
mg/day without preload if already on aspirin. Patients received an
intra-arterial dose of 100 to 140 U/kg heparin at time of procedure.
Use of periprocedural glycoprotein IIb/IIIa inhibitors was allowed, at
the operator's discretion.Table 1
Baseline characteristics of all groups.
All patient Clopidogrel sensitive C
Number 107 75 (70.10%) 1
Age (years) 57.91 ± 8.15 57.52 ± 8.64 5
Female 24 (22.4%) 15 (20%) 3
Weight 69.22 ± 7.43 68.69 ± 8.00 6
Diabetic 39 (36.4%) 27 (36%) 6
Hypertensive 58 (54.2%) 43 (57.3%) 6
Smoker 18 (16.8%) 12 (16%) 4
Tobacco chewer 18 (16.8%) 16 (21.3%) 0
Family history 5 (4.7%) 3 (4%) 1
LDL cholesterol (mg/dl) 7.3.02 ± 25.70 75.4 ± 27.62 5
HDL cholesterol (mg/dl) 31.63 ± 7.28 32.0 ± 6.76 2
Total cholesterol (mg/dl) 131.42 ± 29.35 133.48 ± 30.18 1
Triglyceride (mg/dl) 127.24 ± 54.34 122.25 ± 41.78 1
CSA 54 (50.5%) 35 (46.7%) 6
USA 4 (3.7%) 4 (5.3%) 0
NSTEMI 10 (9.3%) 8 (10.7%) 0
MI 36 (33.6%) 24 (32%) 4
Old MI 21 (19.6%) 17 (22.7%) 3
Prior CABG 3 (2.8%) 3 (4%) 0
Prior PCI 10 (9.3%) 7 (9.3%) 1
LV dysfunction 38 (35.5%) 27 (36%) 52.3. Follow-up
All patients with PCI were followed up in cardiology outpatient de-
partment at 30 days.
2.4. Assessment of platelet function
Blood samples were collected for platelet function testing before the
clopidogrel LD (baseline), at 6 h ormore after clopidogrel loading. Plate-
let function test was done using Light transmission aggregometry (LTA)
assay (Chrono-log corporation, USA, Model 700 Whole Blood/Optical
Lumi-Aggregometer), using doses of 5 μmol/L ADP as agonist and re-
ported as a percentage of Maximal Platelet Aggregation (MPA).
Clopidogrel resistant patient (High on Treatment Platelet Reactivity
{HTPR}) was deﬁned as MPA N46% for a 5-μmol/L ADP-induced platelet
aggregation [2]. Platelet function testing was done again 2 h after
reloadingwith one of the three regimens in Patients with High on treat-
ment platelet reactivity (HTPR). Platelet function testing was done in
patients who had PCI on day 1 and day 30 post-PCI. Samples were proc-
essed within 1 h by operators who were blinded to treatment.
2.5. Endpoints
The primary endpoint of study was to compare efﬁcacy of
clopidogrel reloading vs. switching to prasugrel or ticagrelor in patients
with High on treatment platelet reactivity (HTPR) after clopidogrel load
by comparing MPA% on each of the three drug regimen at 2 h post-re-
load and on day 1 post-PCI. Also the efﬁcacy of maintenance dose in
the HTPR patients was compared with clopidogrel sensitive patients
by comparing MPA% at end of 30 days in different study groups.
The secondary endpoint of study was a composite of major adverse
cardiovascular and cerebrovascular events (MACCE) which included
cardiac death, myocardial infarction, stent thrombosis; stroke and
need for repeat revascularisation at time of hospital discharge and
post-PCI at 30 day hospital visit. Stent thrombosis was labelled as
acute, subacute, late and very late when event occurred within 24 h,
30 days, b1 year or N1 year respectively after procedure. Deﬁnite,
probable and possible stent thrombosis was deﬁned according to ARC
deﬁnition [20].
Safety endpoints included bleeding complications and death from
any cause at time of hospital discharge and at post-PCI 30 daylopidogrel reload Prasugrel reload Ticagrelor reload p value
0 (9.30%) 10 (9.30%) 12 (11.20%)
9.90 ± 7.85 59 ± 7.13 57.75 ± 6.32 0.81
(30%) 2 (20%) 4 (33%) 0.697
8.70 ± 6.73 73.10 ± 3.54 69.75 ± 6.15 0.364
(60%) 3 (30%) 3 (25%) 0.353
(60%) 5 (50%) 4 (33.3%) 0.456
(40%) 1 (10%) 1 (8.3%) 0.185
(0%) 1 (10%) 1 (8.3%) 0.255
(10%) 1 (10%) 0 (0%) 0.585
9.5 ± 12.55 78.80 ± 20.12 64.67 ± 21.49 0.158
6.40 ± 8.5 35.70 ± 7.04 30.33 ± 7.87 0.029
15.6 ± 18.21 131.42 ± 29.35 125 ± 25.78 0.204
26.2 ± 86.83 130.6 ± 68.31 156.5 ± 74.96 0.247
(60%) 6 (60%) 6 (50%) 0.771
(0%) 0 (0%) 0 (0%) 0.621
(0%) 1 (10%) 1 (8.3%) 0.752
(40%) 3 (30%) 5 (41.7%) 0.879
(30%) 1 (10%) 0 (0%) 0.200
(0%) 0 (0%) 0 (0%) 0.725
(10%) 2 (20%) 0 (0%) 0.461
(50%) 3 (30%) 3 (25%) 0.651
Table 2







Number 107 75 (70.10%) 32 (29.9%)
Age (years) 57.91 ± 8.15 57.52 ± 8.64 58.81 ± 6.90 0.455
Female 24 (22.4%) 15 (20%) 9 (28.1%) 0.356
Weight 69.22 ± 7.43 68.69 ± 8.00 70.47 ± 5.80 0.260
Diabetic 39 (36.4%) 27 (36%) 12 (37.5%) 0.883
Hypertensive 58 (54.2%) 43 (57.3%) 15 (46.9%) 0.320
Smoker 18 (16.8%) 12 (16%) 6 (18.8%) 0.728
Tobacco chewer 18 (16.8%) 16 (21.3%) 2 (6.2%) 0.056
Family history 5 (4.7%) 3 (4%) 2 (6.2%) 0.614
LDL cholesterol
(mg/dl)
7.3.02 ± 25.70 75.4 ± 27.62 67.47 ± 19.80 0.145
HDL cholesterol
(mg/dl)
31.63 ± 7.28 32.0 ± 6.76 30.78 ± 8.44 0.431
Total cholesterol
(mg/dl)
131.42 ± 29.35 133.48 ± 30.18 126.59 ± 27.14 0.268
Triglyceride (mg/dl) 127.24 ± 54.34 122.25 ± 41.78 138.93 ± 75.70 0.147
CSA 54 (50.5%) 35 (46.7%) 18 (56.2%) 0.364
USA 4 (3.7%) 4 (5.3%) 0 0.184
NSTEMI 10 (9.3%) 8 (10.7%) 2 (6.2%) 0.472
MI 36 (33.6%) 24 (32%) 12 (37.5%) 0.581
Old MI 21 (19.6%) 17 (22.7%) 4 (12.5%) 0.225
Prior CABG 3 (2.8%) 3 (4%) 0 0.251
Prior PCI 10 (9.3%) 7 (9.3%) 3 (9.4%) 0.995
LV dysfunction 38 (35.5%) 27 (36%) 11 (34.4%) 0.872
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according to the TIMI (Thrombolysis in Myocardial Infarction)
criteria [16].Fig. 1. Comparison of baseline plat2.6. Statistical analysis
Statistical analysis was done using IBM SPSS Statistical Software
(IBM SPSS Statistics version 20.0, IBM SPSS, USA).
Continuous variables were expressed asmean± standard deviation
(SD) and categorical variables were expressed as percentage. For con-
tinuous characteristics, means of the treatment groups were compared
using analysis of covariance. For continuous characteristics, means of
the clopidogrel sensitive and patients with High on treatment platelet
reactivity (HTPR) group were compared using independent sample
t-test. For categorical characteristics, percents were compared by
chi-square tests.Means ofMPA (Maximal Platelet Aggregation) of treat-
ment groups were compared using analysis of covariance and compar-
ison between two groups was done using independent sample t- test.
Descriptive analysis was used for MACCE and safety end points because
the trial was not adequately sized to evaluate clinical endpoints. All
tests were 2-tailed, and statistical signiﬁcance was considered for
p values b 0.05.
3. Results
3.1. Patient population
107 patientswere enrolled in study fromOctober 2013 to 1stweek of
November 2014. Of these, 75 (70.1%) patients were clopidogrel sensitive
and 32 (29.9%) were found to have HTPR. Of those with HTPR 10 (9.3%)
patients were reloaded with extra 300 mg clopidogrel, 10 (9.3%) were
reloaded with prasugrel and 12 (11.2%) with ticagrelor. Out of the total
of these 107 patients analysed, 73 underwent PCI; all had the mainte-
nance phase study completed; 52 (71.2%) patients were clopidogrelelet function between groups.
Fig. 2. Comparison of platelet function 2 h after reloading between groups.
17S. Khasa et al. / Clinical Trials and Regulatory Science in Cardiology 13 (2016) 14–20sensitive, 21 (28.8%) patients had HTPR; 7 (9.6%) were reloaded with
clopidogrel, 5 (6.9%) with prasugrel and 9 (12.3%) with ticagrelor.3.2. Basic demographic proﬁle
Demographics and baseline characteristics for the total population
and treatment groups are summarized in Table 1. Mean age of the pa-
tients was 57.9 ± 8.15 year. Men comprised 83 (78.6%) and females
constituted 24 (22.4%) patients. A total of 39 (36.4%) patients were dia-
betics. All were on oral antidiabetics and none of these patients was on
insulin therapy. HTN was present in 58 (54.2%) and 18 (16.8%) were
current smokers.
The most common clinical presentation was stable angina in
54 (50.5%) followed by ST elevation myocardial infarction (STEMI)
36 (33.6%). Non-ST elevation myocardial infarction (NSTEMI) was the
admission diagnosis in 10 (9.3%) and 4 (3.7%) presented with unstable
angina (USA). 38 (35.5%) patients had LV dysfunction. Prior PCI was
done in 10 (9.3%) and 3 (2.8%) patient had prior history of CABG.
Single vessel disease was present in 43 (40.2%) patients whereas
double vessel and triple vessel disease was present in 32 (29.9%) and
23 (21.5%) patients respectively. Normal coronaries were found in 9Table 3





2 h after reload platelet function 42.60 ± 12.48 (n = 10) 14.58 ± 7.20 (n = 12
First day post-Ptca platelet function 43.71 ± 13.46 (n = 7) 12.67 ± 4.58 (n = 9)
Thirty Day post-Ptca Platelet function 50.43 ± 13.11 (n = 7) 13.89 ± 5.11 (n = 9)(8.4%) patients. Procedures were completed through radial route in 98
(91.6%) patients.
All patients received aspirin, beta blockers, statins and heparin. GP
IIb/IIIa inhibitors were used in 63 (58.9%) patients.
Demographics and baseline characteristics for the clopidogrel sensi-
tive and HTPR patients are summarized in Table 2, and showed no sig-
niﬁcant differences among the groups.3.3. Pharmacodynamic evaluations
Baseline platelet aggregability in the study cohort was 58.2 ± 20.7%.
This baseline MPA was signiﬁcantly lower in those diagnosed
clopidogrel sensitive when compared with those diagnosed clopidogrel
resistant (51.4± 19.9% vs. 74.3± 11.7%, p b 0.001) as depicted in Fig. 1.
Fig. 2 shows a comparison of 2 h platelet aggregation study after
reloading of HTPR patients. Platelet aggregation showed a decrease at
2 h post-switching to any of three drug regimen. MPA reduced from
59.7 ± 5.2% to 42.6 ± 12.5% with clopidogrel reload patients vs
57.3 ± 3.7% to 15.80 ± 8.6% with prasugrel reload and 59.5 ± 7.8%
to 14.6 ± 7.2% with ticagrelor reload. MPA was signiﬁcantly low
with prasugrel and ticagrelor reload as compared to clopidogrel reloadPrasugrel reload
(Gp. 3)
p value
(Gp. 1 vs Gp. 2)
p value
(Gp. 1 vs Gp. 3)
p value
(Gp. 2 vs Gp. 3)
) 15.80 ± 8.64 (n = 10) b0.001 b0.001 0.722
15.40 ± 5.60 (n = 5) b0.001 b0.001 0.341
15 ± 9.67 (n = 5) b0.001 b0.001 0.780
Fig. 3. Comparison of platelet function ﬁrst day post-PCI between groups.
Fig. 4. Comparison of platelet function thirty day post-PCI between groups.
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(Gp. 1 vs Gp. 2)
p value
(Gp. 1 vs Gp. 3)
p value
(Gp. 1 vs Gp. 4)
First day post-Ptca
platelet function
21.56 ± 12.87 (n = 52) 43.71 ± 13.46 (n = 7) 12.67 ± 4.58 (n = 9) 15.40 ± 5.60 (n = 5) b0.001 0.341 0.297
Thirty day post-Ptca
platelet function
26.10 ± 12.91 (n = 52) 50.43 ± 13.11 (n = 7) 13.89 ± 5.11 (n = 9) 15 ± 9.67 (n = 5) b0.001 0.780 0.067
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ticagrelor reload. (15.80 ± 8.6% vs 14.6 ± 7.2%, p = 0.722).
Table 3 and Fig. 3 shows comparison of MPA% of three treatment
regimen in HTPR patients on day 1 post-PCI and Fig. 4 at day 30 post-
PCI. At ﬁrst post-PCI day, MPA were 12.6 ± 4.6%, 15.4 ± 5.6% and
43.7 ± 13.4% and at 30 day post-PCI were 13.9 ± 5.1%, 15 ± 9.7% and
50.4 ± 13.1% in ticagrelor, prasugrel and clopidogrel reload groups
respectively. Clopidogrel reload group had signiﬁcantly higher
MPA as compared to prasugrel or ticagrelor at day 1 or at day 30 post-
PCI (p b 0.001). No signiﬁcant difference was observed between
ticagrelor and prasugrel.
A comparison of MPA in clopidogrel sensitive group with all three
treatment regimen for HTPR patients are depicted in Table 4. At ﬁrst
post-PCI day, MPA were 12.6 ± 4.6%, 15.4 ± 5.6%, 21.5 ± 12.9%,
43.7 ± 13.4% and at 30 day post-PCI, MPA were 13.9 ± 5.1%, 15 ±
9.7%, 26.1 ± 12.9%, 50.4 ± 13.1% in ticagrelor, prasugrel, clopidogrel
sensitive and clopidogrel reload groups respectively. No signiﬁcant dif-
ference was observed between ticagrelor, prasugrel and clopidogrel
sensitive group at ﬁrst day or at day 30 post-PCI. Clopidogrel reload
group had signiﬁcantly higher MPA as compared to clopidogrel sensi-
tive group at day 1 or at day 30 post-PCI (p b 0.001).
50% of HTPR patients reloaded with clopidogrel continued to have
HTPR after 2 h of reloading and same results were present at end of
30 days post-PCI whereas all patients loaded with prasugrel or
ticagrelor had no HTPR at end of 2 h or at end of 30 days post-PCI.
3.4. MACCE
No cardiac death, myocardial infarction, Stent thrombosis, stroke
and need for repeat revascularisation occurred during hospital stay or
at post-PCI 30 day hospital visit in any of treatment groups.
3.5. Safety end points
Bleeding complications in different treatment groups is shown in
Table 5.
At time of discharge, six clopidogrel sensitive patients experienced
minor bleeding events; 4 radial haematomas, one femoral haematoma
and one gum bleed. Among the HTPR patients, one patient each in
clopidogrel reload group and ticagrelor loading group had radial
haematoma. One patient had radial haematoma and one patient had
nasal bleed in prasugrel group.
At 30 day post-PCI follow-up, in clopidogrel sensitive group one pa-
tient had skin petechiae, another patient had skin ecchymoses. One pa-
tient in ticagrelor group had skin ecchymoses. No TIMI major or TIMITable 5













At time of discharge
minor bleed
6 (8.0%) 1 (10%) 1 (8.3%) 2 (20%)
30 day minor bleed 8 (10.66%) 1 (10%) 2 (16.6%) 2 (20%)moderate bleeding or deaths due to any cause occurred in any group
at time of discharge or at 30 days post-PCI follow-up.4. Discussion
The present study revealed that about 30% patients had High on
Treatment Platelet Reactivity (HTPR) after loading with 600 mg
clopidogrel as assessed by 5 μM ADP Light transmission aggregometry
(LTA) assay. HTPR observed in our population was higher than Kumar
et al. study (15.3%) in Indian population; Gaglia et al. study (23.1%) in
US population and The RECLOSE 2-ACS (14%) in European population
[7,21,22]. There are however other studies which have observed a
higher HTPR, like the GRAVITAS trial (40.8%), Breet et al. (42.4%) and
Alexopoulos et al. (35.8%) in line with as observed by us [23,24,18].
Our study found no difference between clopidogrel sensitive and
HTPRpatient group in termof baseline characteristics. This is in contrast
to RECLOSE 1 and RECLOSE 2-ACS studywhich showedHTPR to be asso-
ciated with older age, previous history of MI, diabetes mellitus, hyper-
cholesterolemia and low ejection fraction which were not correlated
in our study [7,23,24]. Our results seem logical as resistance is related
to genetic background. Clopidogrel resistance is primarily based on
metabolic phenotype of hepatic cytochrome 2C19 (CYP2C19) genotype.
Patients who are carriers of loss-of-function alleles in the CYP2C19 sys-
tem have low clopidogrel active metabolite levels and are thus
clopidogrel resistant [3,4]. Clopidogrel resistance is not evidenced by
any of demographic features of the patient. Had this been so, it would
have been easy to identify patients who could be clopidogrel resistant
and we know from clinical knowledge, this is not so.
Our study assessed pharmacodynamic effects of clopidogrel
reloading vs. switching to newer agents in this group of HTPR patients.
We found that 50% (5/10) of HTPR patients reloaded with clopidogrel
continued to have HTPR while the same was resolved completely in all
the patients switched to the newer agents' viz. prasugrel or ticagrelor.
Bonello et al. showed that even after 2400-mg loading dose of
clopidogrel, 8% of patients continued to have HTPR [25]. The GRAVITAS
trial showed that in patients with HTPR a higher maintenance dose
clopidogrel (150 mg) led to a 22% lower prevalence of HTPR compared
with standard-dose clopidogrel at 30 days and 6 months, an effect ob-
served by us in the tune of 50% [23]. RECLOSE 2-ACS study revealed
38% of HTPR patients would still have HTPR after adjusting antiplatelet
therapy to very high maintenance dose (300 mg) [7]. Thus with HTPR
patients continued on different protocols of clopidogrel dosing only a
small proportion could be brought in the clopidogrel sensitive range
while large majority continued to have HTPR.
Reloading with newer P2Y12 receptor antagonist (ticagrelor/
prasugrel) showed complete disappearance of clopidogrel resistant
(HTPR) both at 2 h of reloading and during maintenance phase up to
30 days. These results were similar to those shown in study of
Alexopoulos et al. and the SWAP 2 study [26,27]. Further, there was
no intergroup difference between the two agents' viz. prasugrel and
ticagrelor. HTPR patients receiving prasugrel/ticagrelor had MPA in
the same range as clopidogrel sensitive patients or even better.
Thus in HTPR patients, patient should be reloaded with either
prasugrel or ticagrelor for better pharmacodynamic effects, butwhether
it would lead to clinical outcome beneﬁt is still not certain.
20 S. Khasa et al. / Clinical Trials and Regulatory Science in Cardiology 13 (2016) 14–204.1. Limitations of study
Sample size of our study was small, so pharmacodynamics could be
assessed but evaluation of clinical beneﬁts was not possible.
4.2. Conclusion
In patients undergoing PCI exhibitingHTPR after clopidogrel loading,
ticagrelor or prasugrel reloading produced improved platelet inhibition
which was better than clopidogrel reload and this effect was sustained
through maintenance phase up to 30 days post-PCI at least.
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